via Wikipedia
Clears the Way for Drug Development for Skeletal Muscle Diseases
A researcher at the University of Houston College of Pharmacy has identified the proteins necessary for efficient regeneration of skeletal muscles after acute injury and in Duchenne Muscular Dystrophy (DMD). Ashok Kumar, Else and Philip Hargrove Endowed Professor of Pharmacological and Pharmaceutical Sciences, is reporting his findings in eLife.
Skeletal muscles, which connect your bones and allow you to move, contain 50-75% of all the body’s proteins. Not only are they the most abundant and dynamic tissue of the human body essential for posture, locomotion and breathing, but they also control the body’s entire metabolism.
So, when skeletal muscles get hurt or injured either through trauma or degenerative disease, it can become complicated.
“We identified that the IRE1 protein – localized on the membrane of endoplasmic reticulum (the organelle that is involved in the production, folding and quality control of proteins) and XBP1 protein are important for efficient regeneration of skeletal muscle after injury and in DMD,” reports Kumar. Anirban Roy, research assistant professor of pharmacology, is the paper’s first author.
Understanding the mechanisms of skeletal muscle regeneration is essential for the development of new therapeutics aimed at treating various genetic and acquired degenerative muscle disorders.
“We found that skeletal muscle repair was considerably diminished in models in which IRE1 or XBP1 protein was specifically removed from skeletal muscle. These proteins support skeletal muscle regeneration through enhancing the proliferation of resident muscle stem cells. Deletion of IRE1 in skeletal muscle reduces abundance of muscle stem cells and exaggerates muscular dystrophy phenotype,” said Kumar.
Ongoing studies in the Kumar laboratory are investigating whether recently developed highly specific pharmacological activators of IRE1 and XBP1 can improve skeletal muscle regeneration after acute injury and other muscle degenerative diseases.
“The research work has enormous scope for drug development for skeletal muscle diseases,” said Kumar.
Original Article: Breakthrough Identification of Proteins Necessary for Muscle Regeneration
More from: University of Houston
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Regeneration of skeletal muscles
- Application of Mesenchymal Stem Cells in the Regeneration of Musculoskeletal Tissues
The ultimate goal is directed cellular regeneration of damaged or diseased ... [19] In addition, these cells also may have a role in the skeletal maintenance of patients at risk for osteoporosis.
- Satellos Bioscience Announces 2021 Year End Financial Results And Operational Highlights
Our scientists discovered what we believe to be a previously unrecognized root cause of skeletal ... divide to create muscle progenitor cells, lead to a failure of muscle regeneration in Duchenne ...
- Satellos Bioscience Announces 2021 Year End Financial Results and Operational Highlights
Our scientists discovered what we believe to be a previously unrecognized root cause of skeletal muscle degeneration ... muscle stem cells divide to create muscle progenitor cells, lead to a failure ...
- Calpain 3 Is Important for Muscle Regeneration
To be able to determine if mutations in specific domains of CAPN3 affect regeneration more than others ... grade 3 = evident muscle weakness, stepping gait, climbing stairs with banister; grade ...
- Satellos Bioscience Inc. Invited to Present at the 2022 Bloom Burton & Co. Healthcare Investor Conference
Our scientists discovered what we believe to be a previously unrecognized root cause of skeletal ... divide to create muscle progenitor cells, lead to a failure of muscle regeneration in Duchenne ...
Go deeper with Google Headlines on:
Regeneration of skeletal muscles
Go deeper with Bing News on:
Drug development for skeletal muscle diseases
- NeuBase Therapeutics Reports Business Update and Financial Results for the Second Quarter of Fiscal Year 2022
Investigational New Drug (IND)-enabling studies continue to generate promising data that support further development of the company’s lead myotonic dystrophy type 1 (DM1) candidate; new preclinical ...
- FDA grants orphan drug designation for Duchenne muscular dystrophy treatment
“We look forward to further discussions with the FDA regarding our development initiatives, which we hope will bring new options to patients suffering from this devastating disease ... initially ...
- Stealth BioTherapeutics Receives Orphan Drug Designation from FDA for Elamipretide for Treatment of Duchenne Muscular Dystrophy
The company also announced that the FDA's Division of Neurology I has granted its request for a pre-IND meeting to discuss a development ... of muscle function. The disease, which is typically ...
- Stealth BioTherapeutics Receives Orphan Drug Designation from FDA for Elamipretide for Treatment of Duchenne Muscular Dystrophy
Advisor Insights Personal Finance Market Volatility Retirement Planning Start Investing Save for College Best Investments See All ...
- Stealth BioTherapeutics Receives Orphan Drug Designation from FDA for Elamipretide for Treatment of Duchenne Muscular Dystrophy
Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies for diseases involving mitochondrial ...
